NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.8000
0.0000 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.8000
Open0.8200
Bid0.7000 x 1800
Ask0.8100 x 3200
Day's Range0.7601 - 0.8300
52 Week Range0.4900 - 5.6000
Volume77,711
Avg. Volume89,000
Market Cap14.448M
Beta (3Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-1.2400
Earnings DateMar 24, 2017 - Mar 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of NAVB earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire

    Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the H.C.

  • Business Wire

    Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results

    Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in Anaheim, CA have been highlighted with a press release by the SNMMI (http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=31987). The presentation, titled “A Phase I/Phase II Study of Intravenously (“IV”) Administered Tc99m Tilmanocept (“TCT”) to Determine Safety, Tolerability, Optimal Clinical Dose Selection, and Imaging Timepoint in Patients Clinically Diagnosed with Rheumatoid Arthritis (“RA”)" was delivered at the Society’s Annual Meeting on Sunday, June 23, 2019 by Arash Kardan, M.D. In addition, an abstract of the presentation will be published in a future edition of the Journal of Nuclear Medicine.

  • Business Wire

    Navidea Biopharmaceuticals Announces Closing of Public Offering of Common Stock

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the closing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $0.75 per share. Of the total shares sold in the offering, 4,000,000 shares were placed with John Kim Scott, Jr., a principal stockholder in the Company, who agreed to purchase such shares at a purchase price of $0.75 per share.

  • Thomson Reuters StreetEvents

    Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT

    Q1 2019 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire

    Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce the details of an oral presentation on the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in Anaheim, CA. The presentation, titled “A Phase I/Phase II Study of Intravenously (“IV”) Administered Tc99m Tilmanocept (“TCT”) to Determine Safety, Tolerability, Optimal Clinical Dose Selection, and Imaging Timepoint in Patients Clinically Diagnosed with Rheumatoid Arthritis (“RA”)" will be delivered at 12:30 PM, Sunday, June 23, 2019 by Arash Kardan, M.D. In addition, an abstract of the presentation will be published in a future edition of the Journal of Nuclear Medicine.

  • Business Wire

    Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the pricing of its previously announced underwritten public offering of 8,000,000 shares of common stock at a price to the public of $0.75 per share. Navidea has also granted the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • Business Wire

    Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Navidea also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock to be sold in the offering at the public offering price, less underwriting discounts and commissions in such underwritten offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Business Wire

    Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property

    On June 12, 2019, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware issued an oral ruling granting the motion of Macrophage Therapeutics, Inc. (“MT”), a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), to declare as void certain transactions putatively authorized by MT’s former Chief Executive Officer, Dr. Michael Goldberg (“Dr. Goldberg”), pursuant to which Dr. Goldberg purported to transfer certain of Navidea’s intellectual property rights (which had been assigned to MT) to a company controlled by Dr. Goldberg.

  • Associated Press

    Navidea: 1Q Earnings Snapshot

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 24 cents. The biopharmaceutical posted revenue of $136,000 in the period. In the final minutes of trading on Wednesday, the company's ...

  • Business Wire

    Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

    Conference Call to be held Wednesday, May 8, 2019 at 5:00 pm ET

  • Business Wire

    Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

    Conference Call to be held Wednesday, May 8, 2019 at 5:00 p.m.

  • Business Wire

    Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”)

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Professor Mike Sathekge, MBChB, M. Med (Nuclear Medicine), PhD Professor and Head of the Department of Nuclear Medicine in the Faculty of Health Sciences at the University of Pretoria/Steve Biko Academic Hospital, plans to initiate a comparative study evaluating the use of Tilmanocept in patients with TB. A molecular probe such as 68Ga-labeled Tilmanocept targeting MR (CD206) expressed on macrophages, therefore, holds great promise not only in understanding the behavior of TB granulomas, but may serve as a vehicle for delivering therapeutic interventions in the future.

  • Business Wire

    Navidea Biopharmaceuticals Announces Reverse Stock Split

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a one-for-twenty reverse stock split of its issued and outstanding shares of common stock. The reverse split will be effective at 12:01 a.m. (EDT) on April 26, 2019, and shares of the Company’s common stock will begin trading on a split-adjusted basis when the NYSE American market opens on that date.

  • Business Wire

    Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received feedback from the U.S Food and Drug Administration (“FDA”) regarding the Company’s planned clinical studies that will evaluate joint disease in patients with Rheumatoid Arthritis (“RA”) and monitor patient response to therapy. The Company’s proposed RA studies were discussed with the FDA during an in-person meeting, and through follow-up collaborative efforts.

  • Business Wire

    Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Arash Kardan, M.D., will give an oral presentation on the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in June 2019. Images were acquired one hour and three hours post-injection of Tc99m tilmanocept. Results from the completed trial demonstrate that Tc99m tilmanocept is well-tolerated with no serious adverse events, adverse drug reactions, or drug-related adverse events observed.

  • Business Wire

    Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced execution of a Stock Purchase Agreement (the “Purchase Agreement”) with an existing investor, John K. Scott, Jr. (the “Investor”), pursuant to which the Company will issue to the Investor in a private placement (the “Private Placement”) up to $3.0 million in shares (the “Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).

  • Thomson Reuters StreetEvents

    Edited Transcript of NAVB earnings conference call or presentation 7-Mar-19 10:00pm GMT

    Q4 2018 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire

    Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

    Conference Call to be held Thursday, March 7, 2019 at 5:00 pm ET

  • Business Wire

    Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update

    Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Thursday, March 7th, 2019, at 5:00 pm ET to discuss its financial results for the fourth quarter of 2018 in conjunction with the filing of its annual report on Form 10-K. Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance and Administration, of Navidea will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the financial earnings portion of the conference call.

  • Business Wire

    Navidea Biopharmaceuticals Announces Extension of NYSE American Listing

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the receipt of a notice from the NYSE American LLC (the “NYSE American”) on January 28, 2019 that the NYSE American has granted the Company an extension until March 31, 2019 to regain compliance with Section 1003(f)(v) of the NYSE American’s continued listing standards. Navidea previously disclosed that it received a notification from the NYSE American stating that Navidea was not in compliance with certain provisions of the NYSE American continued listing standards, including Section 1003(f)(v), which relates to the selling price per share of the Company’s securities.

  • Business Wire

    Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a Writ of Prohibition against the Honorable Mark A. Serrott asserting that Judge Serrott's refusal to dismiss Navidea Biopharmaceuticals, Inc.'s pending Ohio litigation against CRG was improper and that Judge Serrott lacked jurisdiction over CRG with respect to the case issues.